Propanc Biopharma, Inc. (PPCB)
NASDAQ: PPCB · Real-Time Price · USD
0.0930
+0.0025 (2.76%)
At close: May 13, 2026, 4:00 PM EDT
0.0926
-0.0004 (-0.43%)
After-hours: May 13, 2026, 7:12 PM EDT
Propanc Biopharma Employees
As of June 30, 2025, Propanc Biopharma had 2 total employees, including 1 full-time and 1 part-time employees. The number of employees did not change compared to the previous year.
Employees
2
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$33,500,093
Market Cap
1.94M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Jun 30, 2025 | 2 | 0 | - | 1 | 1 |
| Jun 30, 2024 | 2 | 0 | - | 1 | 1 |
| Jun 30, 2023 | 2 | -1 | -33.33% | 1 | 1 |
| Jun 30, 2022 | 3 | 1 | 50.00% | 1 | 2 |
| Jun 30, 2021 | 2 | -1 | -33.33% | 1 | 1 |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Valion Bio | 52 |
| Jaguar Health | 47 |
| HCW Biologics | 36 |
| Scinai Immunotherapeutics | 31 |
| AIM ImmunoTech | 21 |
| Silexion Therapeutics | 14 |
| Biodexa Pharmaceuticals | 11 |
| Artelo Biosciences | 7 |
PPCB News
- 1 hour ago - Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans - GlobeNewsWire
- 4 weeks ago - Propanc Biopharma files to sell 15M shares of common stock for holders - TheFly
- 7 weeks ago - Propanc Biopharma signs multi-year collaboration with Spanish universities - TheFly
- 7 weeks ago - Propanc Biopharma Executes Multi-Yr, Anti-Aging & Cancer Research Collaboration with the Universities of Jaén and Granada, Spain - GlobeNewsWire
- 2 months ago - Propanc Biopharma announces highlights of PRP - TheFly
- 2 months ago - Propanc Biopharma Targets $3B+ Pancreatic Cancer Market with PRP: 85%+ Tumor Inhibition in Breakthrough Proenzyme Therapy - GlobeNewsWire
- 2 months ago - Propanc Biopharma executes service agreement with FyoniBio - TheFly
- 2 months ago - Propanc Biopharma Executes Service Agreement with FyoniBio to Establish & Validate Pharmacokinetics Assay for Phase 1b First-In-Human Study - GlobeNewsWire